Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors

US9475817B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Upender Velaparthi · Princeton Junction, US
• Chetan Padmakar Darne · Orange, US
• Dharmpal S. Dodd · Princeton, US
• Peiying Liu · Madison, US
• Christopher P. Mussari · Princeton, US
• Mark D. Wittman · Cheshire, US
• Selvakumar Kumaravel · Bengaluru, IN
• Dibakar Mullick · Mahe, IN

Key dates

• Filing date: Dec 20, 2013
• Grant date: Oct 25, 2016
• Expiry date: Dec 20, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.